Last updated: February 21, 2026
What is the Drug Identified as NDC 00143-9159?
NDC 00143-9159 refers to Xywav, a medication approved by the FDA in 2021 for the treatment of cataplexy or excessive daytime sleepiness in narcolepsy patients. It is an oral solution containing an amnestic and anti-cataplectic formulation of gamma-hydroxybutyrate (GHB), marketed by Jazz Pharmaceuticals.
Market Size and Key Drivers
Addressable Patient Population
- Narcolepsy prevalence: Approximately 0.03% to 0.05% worldwide.
- U.S. adult narcolepsy patients: Estimated between 100,000 and 200,000.
- Treatment penetration: Historically low due to lack of awareness, side effects, and limited options before Xywav.
Competitive Landscape
- Prior to Xywav, the primary treatment was Sodium Oxybate (Xyrem), also from Jazz Pharmaceuticals.
- Xywav offers a lower sodium content and alternative dosing regimen, positioning it for improved adherence.
- Competitors include off-label use of stimulants and other wake-promoting agents like modafinil and sodium oxybate.
Market Drivers
- Increased diagnosis rates, driven by improved awareness.
- Growing acceptance of narcolepsy as a chronic condition requiring long-term management.
- Payers increasingly covering GHB-based medications.
Price Analysis and Revenue Trends
Pricing Overview
- Xywav's wholesale acquisition cost (WAC): Approximately $3,000 for a 30-day supply (1.5 grams per night dosage).
- Monthly retail price: Around $3,200–$3,500, depending on pharmacy and insurance coverage.
- Annual cost: Estimated at $38,400–$42,000.
Revenue Performance
- In Q4 2022, Jazz Pharmaceuticals reported Xywav revenue of approximately $78 million globally.
- U.S. sales for the full year 2022 exceeded $300 million.
- Market penetration remains substantial, with steady growth expected due to new diagnoses and expanded payer coverage.
Price Trends
- Slight upward pressure anticipated due to inflation, healthcare policy changes, and increased demand.
- Expected price stability owing to existing patent protections and limited direct competitors.
Regulatory and Patent Status
Patent Protection
- Jazz held multiple patents protecting Xywav and Xyrem through at least 2030.
- These patents cover formulation, manufacturing methods, and dosing regimens, limiting generic entry.
Market Exclusivity
- FDA orphan drug designation and patent protections support market exclusivity until at least 2030.
Future Projections and Market Outlook
| Year |
Estimated Revenue |
Key Assumptions |
| 2023 |
$350 million |
Continued diagnosis growth, stable pricing, expanding payer coverage. |
| 2024 |
$380 million |
Increased awareness, possible new indications, steady market share. |
| 2025 |
$410 million |
Slight upward pricing pressure, no new generic entrants. |
| 2026–2030 |
$400–$450 million annual |
Patent protection persists, market saturation tempers growth. |
Factors Influencing Projections
- Entry of generics after patent expiry (~2030).
- Price negotiations and reimbursement policies.
- Development of alternative therapies or formulations.
- Changes in diagnostic rates and treatment guidelines.
Key Takeaways
- NDC 00143-9159 (Xywav) operates in a niche but growing segment for narcolepsy management.
- Current wholesale prices are around $3,000 per month, with annual revenues surpassing $300 million in the U.S.
- Strong patent protections and market exclusivity project revenues to remain stable through at least 2030.
- Growth will rely on ongoing diagnosis rates, payer coverage, and market penetration.
FAQs
Q1: When will generic versions of Xywav become available?
A1: Patent protection extends until approximately 2030, limiting generic entry until then.
Q2: How does Xywav's pricing compare with Xyrem?
A2: Xywav's monthly costs are similar to or slightly higher than Xyrem's, but its lower sodium content offers a competitive advantage.
Q3: What factors could impact Xywav's market share?
A3: New formulations, competitors entering the space, changes in reimbursement policies, or shifts in diagnosis rates.
Q4: Are there any approved alternative treatments for narcolepsy?
A4: Yes, including stimulants, modafinil, armodafinil, sodium oxybate, and off-label wake-promoting agents.
Q5: How might future healthcare policies influence pricing?
A5: Price regulation or reimbursement negotiations could put downward pressure on prices, impacting revenue projections.
References
- FDA. (2021). FDA approves Xywav for narcolepsy. U.S. Food and Drug Administration.
- Jazz Pharmaceuticals. (2022). Xywav product information and financial reports.
- IQVIA. (2022). U.S. Prescription Market Data.
- MarketResearch.com. (2022). Narcolepsy therapeutics market analysis.
- Centers for Disease Control and Prevention (CDC). (2021). Narcolepsy prevalence estimates.
